AKERO THERAPEUTICS
Akero Therapeutics is committed to providing meaningful treatment options for people with serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by inflammation in the liver and liver cell damage resulting in fibrosis, cirrhosis, liver failure, and death. The company is developing pioneering medicines designed to restore metabolic balance and halt NASH progression. Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 protein and potential best-in-class treatment for NASH. The AKR-001 builds upon two decades of work on FGF21 biology. It is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
AKERO THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2017-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.akerotx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
951.1 M USD
Technology used in webpage:
Google Maps IPv6 ReCAPTCHA Google Maps API COVID-19 Gravity Forms Akismet Akismet Non Hosted Akamai Hosted
Similar Organizations
Ajax Therapeutics
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
TARGAN
TARGAN is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries.
Artiva Biotherapeutics
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Lytica Therapeutics
Lytica Therapeutics, Inc. is a biotechnology company focused on developing novel peptide therapeutics.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Taiga Biotechnologies
Taiga Biotechnologies is a clinical-stage company focused on harnessing the immune system to fight infectious disease and cancer.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Akero Therapeutics
Pfizer Breakthrough Growth Initiative
Pfizer Breakthrough Growth Initiative investment in Post-IPO Equity - Akero Therapeutics
venBio Partners
venBio Partners investment in Series B - Akero Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Akero Therapeutics
LifeSci Venture Partners
LifeSci Venture Partners investment in Series B - Akero Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Akero Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Series B - Akero Therapeutics
Atlas Venture
Atlas Venture investment in Series B - Akero Therapeutics
Boxer Capital
Boxer Capital investment in Series B - Akero Therapeutics
Versant Ventures
Versant Ventures investment in Series B - Akero Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-04-30 | Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer |
| 2023-01-10 | Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy |
Official Site Inspections
http://www.akerotx.com Semrush global rank: 2.11 M Semrush visits lastest month: 9.58 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Akero Therapeutics"
Akero Therapeutics | Efruxifermin (EFX) for MASH
BALANCED. HARMONY. SYMMETRY. SYNCHRONY. These names define our clinical trials because we believe restoring whole-body metabolic balance is the key to addressing metabolic dysregulation—and because we believe EFX is …See details»
Akero Therapeutics | Efruxifermin for MASH | Leadership
Libette Luce is Vice President of Regulatory Affairs at Akero. She brings over 20 years of experience in the pharmaceutical industry with more than 15 years specializing in global regulatory affairs across multiple therapeutic areas …See details»
Akero Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Akero Therapeutics is committed to providing meaningful treatment options for people with serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by inflammation in the …See details»
Akero Therapeutics - LinkedIn
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH.See details»
Akero Therapeutics, Inc. (AKRO) - Yahoo Finance
See the company profile for Akero Therapeutics, Inc. (AKRO) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Investors - Akero Therapeutics, Inc.
The Investor Relations website contains information about Akero Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Akero Therapeutics Company Profile - Office Locations ... - Craft
Oct 22, 2024 Akero Therapeutics has 2 employees across 3 locations. See insights on Akero Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
Akero Therapeutics - Overview, News & Similar companies
Akero Therapeutics contact info: Phone number: (650) 487-6488 Website: www.akerotx.com What does Akero Therapeutics do? Akero Therapeutics is a clinical-stage company …See details»
Akero Therapeutics | EFX for MASH | Fc-FGF21 Fusion …
EFX is currently being evaluated in the Phase 3 SYNCHRONY program, which is comprised of three clinical trials designed to support marketing applications for treatment of pre-cirrhotic MASH as well as compensated cirrhosis due to …See details»
Akero Therapeutics to Present at Upcoming Healthcare …
Nov 10, 2022 Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and Twitter for more information. Investor Contact: Christina Tartaglia Stern …See details»
Press Release Details - ir.akerotx.com
3 days ago Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information. Investor Contact: Christina Tartaglia Precision AQ …See details»
Akero Therapeutics Announces Proposed Public Offering of …
Mar 4, 2024 [email protected]. Media Contact: Sarah O’Connell 732.456.0092 [email protected]. Markets Insider and Business Insider Editorial Teams were …See details»
Akero Therapeutics | Efruxifermin (EFX) for MASH | History
We initiated and dosed the first patients in two parallel, randomized, placebo-controlled Phase 3 trials: SYNCHRONY Histology evaluating the efficacy and safety of EFX in patients with …See details»
Akero Therapeutics Reports Second Quarter 2024 Financial Results …
Aug 9, 2024 The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in …See details»
Akero Therapeutics | EFX for MASH | Our Culture
Akero is a team of problem solvers dedicated to pursuing bold scientific approaches to discovering and developing transformational treatments for patients with serious metabolic …See details»
Press Release Details - ir.akerotx.com
Mar 7, 2024 Visit us at akerotx.com and follow us on LinkedIn and Twitter for more information. Forward Looking Statements Statements contained in this press release regarding matters …See details»
Akero Therapeutics | Metabolic Disease | EFX for MASH
Our current focus is on metabolic dysfunction-associated steatohepatitis (MASH), a severe form of metabolic dysfunction-associated steatotic liver disease marked by whole-body metabolic …See details»
Akero Therapeutics Reports First Quarter 2022 Financial Results
Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year. SOUTH SAN FRANCISCO, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Akero …See details»
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 …
Feb 25, 2022 Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year. SOUTH SAN FRANCISCO, Calif., Feb. 25, 2022 (GLOBE …See details»